Literature DB >> 7897257

Suppressin: an endogenous negative regulator of immune cell activation.

E M Ban1, R D LeBoeuf.   

Abstract

We have recently identified a new suppressor molecule we named suppressin (SPN) that has all the characteristics of a global negative regulator of the immune system. SPN is a unique 63-kD monomeric polypeptide with a pI of 8.1 that is produced and secreted under basal conditions by murine splenocytes, human peripheral mononuclear cells, and hormone-secreting pituitary cells. The biological actions of SPN in vitro include the inhibition of mitogen-induced proliferation and immunoglobulin synthesis of lymphocytes and the suppression of interleukin-2-dependent CTLL-2 cell proliferation. In addition, SPN enhances natural killer cell activity by eliciting interferon-alpha and -beta synthesis and secretion. SPN effects are reversible, nontoxic, and require the continuous presence of exogenous SPN. T lymphocytes stimulated with concanavalin A or phytohemagglutinin are more sensitive to SPN (90% inhibition) than are lipopolysaccharide-stimulated B cells (60% inhibition). SPN arrests lymphocytes in the G0/G1 phase of the cell cycle after reduction of their RNA, protein and DNA synthesis, suggesting that SPN inhibits the processes required for G0 transition to G1. SPN is found intracellularly in all unstimulated lymphocyte subsets, monocytes, and in phytohemagglutinin-activated T lymphocytes immunopositive for the low affinity interleukin-2 receptor. These results suggest that SPN may be a major negative regulator of cell proliferation in the immune system. All SPN-producing cell types are also sensitive to SPN. Collectively, the results of these experiments provide the foundations for a model in which SPN regulates lymphocyte proliferation in an autocrine and/or paracrine manner.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7897257     DOI: 10.1007/bf02918219

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  26 in total

1.  Human lymphoblastoid interferon. Large scale production and partial purification.

Authors:  P J Bridgen; C B Anfinsen; L Corley; S Bose; K C Zoon; U T Rüegg; C E Buckler
Journal:  J Biol Chem       Date:  1977-10-10       Impact factor: 5.157

2.  The importance of being nearest.

Authors:  J H Playfair; H M Dockrell; R Lelchuk
Journal:  Immunol Today       Date:  1984-02

3.  Natural suppressor (NS) cells members of the LGL regulatory family.

Authors:  T Maier; J H Holda; H N Claman
Journal:  Immunol Today       Date:  1986-10

4.  Induction and decay of human fibroblast interferon mRNA.

Authors:  R L Cavalieri; E A Havell; J Vilcek; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

5.  Stimulated rat T cell-derived inhibitory factor for cellular DNA synthesis (STIF). I. Isolation and characterization.

Authors:  K Chiba; T Nishimura; Y Hashimoto
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

6.  A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma.

Authors:  K Asai; T Hirano; S Kaneko; A Moriyama; K Nakanishi; I Isobe; Y Z Eksioglu; T Kato
Journal:  J Neurochem       Date:  1992-07       Impact factor: 5.372

7.  Immunomodulatory characteristics of a novel antiproliferative protein, suppressin.

Authors:  D J Carr; J E Blalock; M M Green; R D LeBoeuf
Journal:  J Neuroimmunol       Date:  1990-12       Impact factor: 3.478

8.  Type beta transforming growth factor from feline sarcoma virus-transformed rat cells. Isolation and biological properties.

Authors:  J Massagué
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

9.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization.

Authors:  R K Assoian; A Komoriya; C A Meyers; D M Miller; M B Sporn
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

10.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.

Authors:  D De Groote; P F Zangerle; Y Gevaert; M F Fassotte; Y Beguin; F Noizat-Pirenne; J Pirenne; R Gathy; M Lopez; I Dehart
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

View more
  2 in total

1.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

2.  Comparative proteomic study of dog and human saliva.

Authors:  Phutsa Sanguansermsri; Howard F Jenkinson; Jitkamol Thanasak; Kongthawat Chairatvit; Sittiruk Roytrakul; Suthathip Kittisenachai; Duangchewan Puengsurin; Rudee Surarit
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.